[Federal Register: April 15, 2005 (Volume 70, Number 72)]
[Notices]
[Page 19964-19965]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr15ap05-75]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Methods for Treating
Inflammatory Bowel Disease Using Cholera Toxin B Subunit
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department
of Health and Human Services, is contemplating the grant of an
exclusive patent license to practice the inventions embodied in U.S.
Patent Application 10/129,907, filed May 10, 2002 [DHHS Ref. E-263-
1999/0-US-03], entitled ``Methods for treating inflammatory bowel
disease using cholera toxin B subunit,'' to SBL Vaccin AB, which is
located in Stockholm, Sweden. The patent rights in these inventions
have
[[Page 19965]]
been assigned to the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of cholera toxin B as a
therapeutic treatment of inflammatory bowel disease, specifically
Crohn's disease.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before June
14, 2005, will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Michelle A. Booden, Ph.D., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; telephone: (301) 451-7337; Facsimile: (301) 402-0220; e-
mail: boodenm@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The technology describes a method of
treating or preventing inflammatory bowel disease by administrating
cholera toxin B subunit (CT-B). Specifically, the patent application
discloses administrating CT-B as a method for treating and preventing
Crohn's disease (CD) and Ulcerative Colitis (UC) as well as a method
for treating and preventing inflammation and/or autoimmune disorders
mediated by increased interferon gamma (INF-[gamma]) and or interleukin
12 (IL-12).
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within sixty
(60) days from the date of this published notice, the NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: April 6, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-7543 Filed 4-14-05; 8:45 am]
BILLING CODE 4140-01-P